A PHASE I STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF HIGH DOSES OF CAMOSTAT MESYLATE IN HEALTHY SUBJECTS PROVIDES A RATIONALE TO REPURPOSE THE TMPRSS2 INHIBITOR FOR THE TREATMENT OF COVID-19